Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

BACKGROUND: Natalizumab, a highly specific α4-integrin antagonist, , has recently been registered across the Middle East and North Africa region. It improves clinical and magnetic resonance imaging (MRI) outcomes and reduces the rate of relapse and disability progression in relapsing-remitting multi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Alroughani, Raed A, Aref, Hany M, Bohlega, Saeed A, Dahdaleh, Maurice P, Feki, Imed, Al Jumah, Mohammed A, Al-Kawi, Muhammad Z, Koussa, Salam F, Sahraian, Mohamad A, Alsharoqi, Isa A, Yamout, Bassem I
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2014
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3927624/
https://ncbi.nlm.nih.gov/pubmed/24521176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-14-27
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk